.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,802,142

« Back to Dashboard

Claims for Patent: 8,802,142

Title:Pharmaceutical compositions comprising levetiracetam and process for their preparation
Abstract: The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation.
Inventor(s): Deleers; Michel (Linkebeek, BE), Hubert; Jean-Beno t (Haaltert, BE)
Assignee: UCB Pharma, S.A. (Brussels, BE)
Application Number:11/910,167
Patent Claims: 1. A pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of a disintegrant selected from polyvinylpolypyrrolidone and sodium croscarmellose, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder selected from macrogol, microcrystalline cellulose, saccharose, mannitol, and sorbitol, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition.

2. The pharmaceutical composition according to claim 1 comprising 3.0 to 7.0% per weight of disintegrant with respect to the total weight of the pharmaceutical composition.

3. The pharmaceutical composition according to claim 1 comprising 0.5 to 2.5% per weight of gliding agent with respect to the total weight of the pharmaceutical composition.

4. The pharmaceutical composition according to claim 1 comprising 0.5 to 4.0% per weight of binder with respect to the total weight of the pharmaceutical composition.

5. The pharmaceutical composition according to claim 1 comprising 0.8 to 1.6% per weight of binder with respect to the total weight of the pharmaceutical composition.

6. The pharmaceutical composition according to claim 1 comprising 0.0 to 0.75% per weight of lubricant with respect to the total weight of the pharmaceutical composition.

7. The pharmaceutical composition according to claim 1 comprising 0.0 to 0.50% per weight of lubricant with respect to the total weight of the pharmaceutical composition.

8. The pharmaceutical composition according to claim 1 comprising 0.08 to 0.15% per weight of lubricant with respect to the total weight of the pharmaceutical composition.

9. The pharmaceutical composition according to claim 1 wherein the sum of disintegrant, gliding agent, binder and lubricant is less than or equal to 20% per weight with respect to the total weight of the pharmaceutical composition.

10. The pharmaceutical composition according to claim 1 wherein the disintegrant is sodium croscarmellose.

11. The pharmaceutical composition according to claim 1 wherein the gliding agent is anhydrous colloidal silica.

12. The pharmaceutical composition according to claim 1 wherein the binder is polyethylene glycol 6000.

13. The pharmaceutical composition according to claim 1 wherein the lubricant is magnesium stearate.

14. The pharmaceutical composition according to claim 1 comprising 2.0 to 9.0% per weight of sodium croscarmellose with respect to total weight of the pharmaceutical composition.

15. The pharmaceutical composition according to claim 1 comprising 0.0 to 3.0% per weight of anhydrous colloidal silica with respect to total weight of the pharmaceutical composition.

16. The pharmaceutical composition according to claim 1 comprising 0.5 to 6.0% per weight of polyethylene glycol 6000 with respect to total weight of the pharmaceutical composition.

17. The pharmaceutical composition according to claim 1 comprising 0.0 to 1.0% per weight of magnesium stearate with respect to total weight of the pharmaceutical composition.

18. The pharmaceutical composition according to claim 1 which comprises 80% to 95% per weight of levetiracetam.

19. The pharmaceutical composition according to claim 1 which comprises a coating agent.

20. The pharmaceutical composition according to claim 19 wherein the coating agent comprises polyvinyl alcohol.

21. The pharmaceutical composition according to claims 19 wherein the coating agent is hydroxypropylmethylcellulose aqueous dispersions.

22. The pharmaceutical composition according to claim 1 which is a tablet.

23. A process of manufacturing a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of a disintegrant selected from polyvinylpolypyrrolidone and sodium croscarmellose, 0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of a binder selected from macrogol, microcrystalline cellulose, saccharose, mannitol, and sorbitol, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, which process comprises: i) mixing levetiracetam, the gliding agent, the disintegrant and the binder, ii) adding the lubricant, iii) mixing levetiracetam, the gliding agent, the disintegrant, the binder and the lubricant; iv) compacting the mixture obtained in iii), v) grinding the mixture obtained in iv), and vi) compressing the mixture obtained in v).

24. The pharmaceutical composition according to claim 1 comprising 250 mg of levetiracetam, 10.75 mg of sodium croscarmellose, 5.188 mg of anhydrous colloidal silica, 2.50 mg of polyethylene glycol 6000, and 0.313 of magnesium stearate.

25. The pharmaceutical composition according to claim 1 comprising 500 mg of levetiracetam, 21.50 mg of sodium croscarmellose, 10.375 mg of anhydrous colloidal silica, 5.00 mg of polyethylene glycol 6000, and 0.625 of magnesium stearate.

26. A pharmaceutical composition made according to the process of claim 23.

27. The pharmaceutical composition according to claim 26 wherein the disintegrant is sodium croscarmellose.

28. The pharmaceutical composition according to claim 26 wherein the gliding agent is anhydrous colloidal silica.

29. The pharmaceutical composition according to claim 26 wherein the lubricant is magnesium stearate.

30. The pharmaceutical composition according to claim 27 comprising 2.0 to 9.0% per weight of sodium croscarmellose with respect to total weight of the pharmaceutical composition.

31. The pharmaceutical composition according to claim 28 comprising 0.0 to 3.0% per weight of anhydrous colloidal silica with respect to total weight of the pharmaceutical composition.

32. The pharmaceutical composition according to claim 29 comprising 0.0 to 1.0% per weight of magnesium stearate with respect to total weight of the pharmaceutical composition.

33. The pharmaceutical composition according to claim 26 comprising 250 mg of levetiracetam, 10.75 mg of sodium croscarmellose, 5.188 mg of anhydrous colloidal silica, 2.50 mg of polyethylene glycol 6000, and 0.313 of magnesium stearate.

34. The pharmaceutical composition according to claim 26 comprising 500 mg of levetiracetam, 21.50 mg of sodium croscarmellose, 10.375 mg of anhydrous colloidal silica, 5.00 mg of polyethylene glycol 6000, and 0.625 of magnesium stearate.

35. The pharmaceutical composition according to claim 1 comprising 750 mg of levetiracetam, 32.25 mg of sodium croscarmellose, 15.563 mg of anhydrous colloidal silica, 7.50 mg of polyethylene glycol 6000, and 24.188 of magnesium stearate.

36. The pharmaceutical composition according to claim 1 comprising 1000 mg of levetiracetam, 43.00 mg of sodium croscarmellose, 20.75 mg of anhydrous colloidal silica, 10.00 mg of polyethylene glycol 6000, and 32.25 of magnesium stearate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc